Merck
CN
  • A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

PloS one (2015-03-31)
Benjamin D Brooks, Kristofer D Sinclair, David W Grainger, Amanda E Brooks
摘要

Nearly 1.3 million total joint replacement procedures are performed in the United States annually, with numbers projected to rise exponentially in the coming decades. Although finite infection rates for these procedures remain consistently low, device-related infections represent a significant cause of implant failure, requiring secondary or revision procedures. Revision procedures manifest several-fold higher infection recurrence rates. Importantly, many revision surgeries, infected or not, require bone void fillers to support the host bone and provide a sufficient tissue bed for new hardware placement. Antibiotic-eluting bone void fillers (ABVF), providing both osteoconductive and antimicrobial properties, represent one approach for reducing rates of orthopedic device-related infections. Using a solvent-free, molten-cast process, a polymer-controlled antibiotic-eluting calcium carbonate hydroxyapatite (HAP) ceramic composite BVF (ABVF) was fabricated, characterized, and evaluated in vivo using a bacterial challenge in a rabbit radial defect window model. ABVF loaded with tobramycin eliminated the infectious burden in rabbits challenged with a clinically relevant strain of Staphylococcus aureus (inoculum as high as 10⁷ CFU). Histological, microbiological, and radiographic methods were used to detail the effects of ABVF on microbial challenge to host bone after 8 weeks in vivo. In contrast to the HAP/BVF controls, which provided no antibiotic protection and required euthanasia 3 weeks post-operatively, tobramycin-releasing ABVF animals showed no signs of infection (clinical, microbiological, or radiographic) when euthanized at the 8-week study endpoint. ABVF sites did exhibit fibrous encapsulation around the implant at 8 weeks. Local antibiotic release from ABVF to orthopedic sites requiring bone void fillers eliminated the periprosthetic bacterial challenge in this 8-week in vivo study, confirming previous in vitro results.

材料
货号
品牌
产品描述

Sigma-Aldrich
甲醛 溶液, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
甲醛 溶液, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
甲基丙烯酸甲酯, contains ≤30 ppm MEHQ as inhibitor, 99%
SAFC
甲醛 溶液, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
甲醛 溶液, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
L-赖氨酸 单盐酸盐, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-赖氨酸 单盐酸盐, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
甲醛 溶液, meets analytical specification of USP, ≥34.5 wt. %
Supelco
L-赖氨酸 单盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甲基丙烯酸甲酯, 99%, stabilized
Supelco
甲醛 溶液, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
甲醛 溶液, tested according to Ph. Eur.
Sigma-Aldrich
聚乙二醇双酚 A 环氧氯丙烷共聚物, mol wt 15,000-20,000 Da
Sigma-Aldrich
L-赖氨酸 单盐酸盐, BioUltra, ≥99.5% (AT)
甲基丙烯酸甲酯, European Pharmacopoeia (EP) Reference Standard
赖氨酸 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
安息香甲基醚, 96%
Supelco
L-赖氨酸 单盐酸盐, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
邻苯二甲酸单丁酯, analytical standard
Supelco
L-赖氨酸盐酸盐 溶液, 100 mM amino acid in 0.1 M HCl, analytical standard
Sigma-Aldrich
邻苯二甲酸单丁酯, 97.0-103.0% (T)
Sigma-Aldrich
安息香甲基醚, 99%
Sigma-Aldrich
甲醛-12C 溶液, 20% in H2O, 99.9 atom % 12C